Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study

Many developing countries lack access to recommended first-line treatments for metastatic renal cell carcinoma (mRCC), such as immune checkpoint inhibitors (ICIs) or ICI-tyrosine kinase inhibitor (TKI) combinations. As a result, predictive markers are necessary to identify patients who may benefit...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Nargiz Majidova, Mustafa Seyyar, Demet Işık Bayraktar, Gülhan Dinç, Elfag İsgandarov, Javid Huseynov, Alper Yaşar, Abdussamet Çelebi, Nadiye Sever, Erkam Kocaaslan, Pınar Erel, Yeşim Ağyol, Ali Kaan Güren, Rukiye Arıkan, Selver Işık, Özlem Ercelep, Güzin Demirağ, Umut Kefeli, Osman Köstek, İbrahim Vedat Bayoğlu, Murat Sarı
Format:	Artigo
Sprog:	Inglês
Udgivet:	Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2024-06-01
Serier:	Biomolecules & Biomedicine
Fag:	International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score renal cell carcinoma (RCC) rosine kinase inhibitor (TKI) long-lasting response
Online adgang:	https://www.bjbms.org/ojs/index.php/bjbms/article/view/10512
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!